A Prospective, Double-Blind, Randomized, Placebo-controlled Clinical Trial of Intracoronary Infusion of Mesenchymal Precursor Cells (MPC) in the Treatment of Patients With ST-Elevation Myocardial Infarction
Latest Information Update: 02 Aug 2024
At a glance
- Drugs Rexlemestrocel-L (Primary)
- Indications Myocardial infarction
- Focus Adverse reactions; Therapeutic Use
- Acronyms AMICI
- Sponsors Angioblast Systems; Mesoblast
- 10 Mar 2022 This trial has been Discontinued in Italy, according to European Clinical Trials Database record.
- 17 Dec 2021 Status changed from active, no longer recruiting to completed.
- 18 Jun 2021 This trial has been completed in Sweden, according to European Clinical Trials Database.